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Treatment-resistant depression (TRD) is a major health concern. More than 40% of patients treated for
major depressive disorder with an appropriate antidepressant dose for an adequate duration fail to
respond. Further, approximately half of adults with major depressive disorder fail to achieve sustained
remission despite various medication trials. The utilization of monoamine oxidase inhibitors (MAOIs)
for the treatment of depression in clinical practice today is low due to their widely known adverse
effects, some of which may be life threatening, and the risk for dietary and drug interactions. For these
reasons, MAOIs are not recommended to be prescribed along with other antidepressants or certain
prescription or nonprescription drugs. Pharmacologic options are limited for individuals with TRD,
however, and there is a paucity of data on the efficacy of MAOIs in combination with other antidepres-
sants for the management of TRD. We performed a search of the PubMed database (inception through
January 25, 2015) to identify cases that illustrate the potential utility, as well as risks, of combination
treatment with MAOIs and other antidepressants for the management of TRD; 18 articles met the crite-
ria for our search. In addition, we performed a retrospective case series by reviewing the medical
records of 29 adults treated for depression with an MAOI plus another psychotropic agent (an antide-
pressant or stimulant medication) between 2003 and 2012 at a large Midwestern teaching hospital. We
compared the findings of the published experience with our local experience to allow for more
informed decisions regarding pharmacotherapy in patients with TRD. We separated the local experi-
ence into two groups: 15 cases with the selective MAO type B inhibitor selegiline combined with medi-
cations presumed to increase the risk of serotonin syndrome and 14 cases with nonselective MAOIs
(phenelzine and tranylcypromine) combined with other contraindicated medications. Although risks of
combination treatment certainly exist with selective serotonin reuptake inhibitors, serotonin and nor-
epinephrine reuptake inhibitors, or clomipramine, the current literature supports cautious use of com-
bining MAOIs with other antidepressants in patients with TRD who have failed multiple treatment
modalities. In addition, the data from the 29 patients receiving combination therapy with an MAOI
and another antidepressant or stimulant medication revealed that 21% improved significantly, with no
complications. This case series and literature review suggest that when used under close supervision
and under the care of an experienced clinician in psychiatry, combination therapy may be a consider-
ation for the management of TRD in patients not responding to monotherapy or other combinations of
antidepressants.
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R E V I E W S O F T H E R A P E U T I C S
Treatment-resistant depression (TRD) is a
major health concern. More than 40% of
patients treated for major depressive disorder
(MDD) with an appropriate antidepressant dose
for an adequate duration fail to respond.1 Fur-
ther, approximately half of adults with MDD fail
to achieve sustained remission despite various
medication trials.2 Despite TRD now being a
major public health concern, there is a paucity
of data for the management of TRD to guide
informed decision-making about pharmacother-
apy. The lack of consensus on the definition of
treatment resistance contributes to the deficiency
of data.3 Definitions range from a poor response
after proper dosing and duration of a single anti-
depressant to response failure after adequate
dosing and duration of two or more antidepres-
sants from different classes,3–5 which has
become the working definition of TRD.2
Monoamine oxidase inhibitors (MAOIs) were
one of the first classes of medications used for
the treatment of depression.6 These agents inhi-
bit the enzyme monoamine oxidase, which is
present in the brain and other tissues such as
the intestine and liver.6 MAOIs currently avail-
able in the United States, including selegiline,
tranylcypromine, phenelzine, and isocarboxazid,
irreversibly bind and inactivate monoamine oxi-
dase, thus preventing the degradation of neuro-
transmitters such as serotonin, epinephrine,
norepinephrine, and dopamine, leading to their
accumulation.6 The use of MAOIs is limited due
to their widely known adverse effects and risk
for dietary and drug interactions. These include
the risk of hypertensive crisis when tyramine-
rich foods are consumed, as well as the risk of
serotonin syndrome, which can occur when MA-
OIs are combined with other medications, which
may be life threatening.6, 7 For this reason, it
has historically been recommended that MAOIs
not be prescribed along with other antidepres-
sants or certain prescription drugs (e.g., tram-
adol, meperidine, dextromethorphan, or
methadone) and nonprescription drugs. Psycho-
tropic agents that are contraindicated or recom-
mended to be used with caution in combination
with MAOIs are listed in Table 1.6, 8, 9 In addi-
tion, a recent case study highlights the concern
for severe hypertension due to the combination
of high caffeine intake in combination with tran-
ylcypromine.10 Given the severity of the risks
involved with using MAOIs, in addition to the
lack of marketing, fear among prescribers, and
lack of experience using MAOIs, the overall use
of these agents in clinical practice today is
low.11
Largely, given the severity of the adverse effects
and reactions, as well as relatively low utilization,
a paucity of data is available on the efficacy of
MAOIs in combination with other antidepressants
for the management of TRD. Considering the lim-
ited pharmacologic options in individuals with
TRD, additional evidence is needed to support the
clinical use of combination antidepressant ther-
apy with MAOIs and other psychotropic agents,
when appropriate. Thus, in this case series and lit-
erature review, we aimed to illustrate the poten-
tial utility, as well as risks, of combination
treatment in patients for the management of TRD
by comparing published experience with our local
experience (case series) to allow for more-
informed decisions regarding pharmacotherapy in
patients with TRD.
It should be highlighted that the cases we
included in the case series are separated into
two groups: cases including the selective MAO
type B inhibitor selegiline and cases including
nonselective MAOIs (phenelzine and tranylcy-
promine). Selegiline confers more selective
MAO-B inhibition at low doses, which improves
tolerability and minimizes risk for dietary inter-
actions with tyramine.12 However, as the dose
increases, selegiline becomes less selective for
MAO-B.13 A wider safety margin exists with the
transdermal formulation of selegiline compared
with nonselective MAOIs and oral selegiline,
even in dosages up to 12 mg/day.14 Enhanced
safety with the transdermal formulation is due
to avoidance of first-pass metabolism and the
ability to minimize the inhibition of MAO-A in
the gastrointestinal tract.12, 14 Although selegi-
line, in any form, still confers risk in combina-
tion with other antidepressants, its selectivity
should be distinguished from that of other non-
selective MAOIs.
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Methods
Literature Review
A literature search of the PubMed database
was performed. Any relevant article available in
English from inception through January 25,
2015, was included. Key search terms included
monoamine oxidase inhibitor, MAOI, selective sero-
tonin reuptake inhibitor, TCA, stimulants, trazo-
done, antidepressants, treatment-resistant
depression, depression, major depressive disorder,
combination, selegiline, phenelzine, and tranylcy-
promine. Controlled and noncontrolled studies,
open-label studies, case reports, and case series
were included.
Case Series
In addition, a retrospective case series was
performed by reviewing the medical records of
29 adult patients treated for depression at a
large Midwestern teaching hospital; this case ser-
ies was approved by the University of Michigan
institutional review board. More specifically, 14
cases of a nonselective (nonselegiline) MAOI
combined with other contraindicated medica-
tions and 15 cases of selegiline combined with
medications presumed to increase the risk of
serotonin syndrome are described. Inclusion cri-
teria consisted of any adult patient (≥ 18 yrs of
age) with a diagnosis of depression who was
treated with an MAOI (tranylcypromine, phenel-
zine, selegiline, or isocarboxazid) plus another
psychotropic agent, including an antidepressant
or stimulant medication, between 2003 and
2012 was included. Of the 29 patients, six cases
were further reviewed and are described in Data
S1. These six cases were representative of the
three most common combinations encountered:
trazodone and an MAOI, tranylcypromine and
other antidepressants, and selegiline and other
antidepressants. A positive and negative clinical
outcome was chosen to exemplify each combina-
tion. Information was gathered to determine
safety of treatment and efficacy of combination
therapy.
Medical records were reviewed and data were
collected on medications used, along with dos-
ages and durations of therapy. Duration of ther-
apy was critical to fully determine the
tolerability of therapy, given the half-lives of cer-
tain antidepressants. Any symptoms and/or
adverse effects that were experienced were docu-
mented to determine tolerability to combination
therapy. Patient demographics, medical and fam-
ily history, summary of illness, indication for
combination treatment, any necessary laboratory
Table 1. Psychotropic Agents Contraindicated or Recommended to Be Used with Caution in Combination with Mono-
amine Oxidase Inhibitors6, 8, 9






























Other antidepressants Bupropion, mirtazapine, St.
John’s wort, maprotiline,
quetiapine, lithium
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values, diet, past medication trials, social his-
tory, and allergies were also collected. Diet was
evaluated based on information provided in the
medical record, given that foods rich in tyramine
may be the cause of any symptoms or adverse
effects. Finally, use of other serotonergic agents
was noted, when applicable.
Results
Eighteen articles were identified and reviewed,
and are described in Table 2.15–32 Additionally,
the medical records of 29 patients that men-
tioned the use of MAOIs in combination with
other antidepressants were reviewed. These data
are presented in two separate tables: Table 3
summarizes 15 cases in which the selective
MAOI selegiline was used, whereas Table 4 sum-
marizes 14 nonselegiline cases. Indications for
combination therapy included depression (eight
cases), TRD (six cases), recurrent MDD (nine
cases), bipolar disorder (five cases), and border-
line personality disorder (one case). Combina-
tions encountered include an MAOI in
combination with either trazodone (16 cases), a
tricyclic antidepressant (TCA) (four cases),
bupropion (two cases), an SSRI (one case), or
mirtazapine (one case). Additionally, MAOIs
were combined with two or more antidepressants
in five cases. Of note, these patients represented
a heterogeneous group, with various indications
and treatment regimens.
Among the 29 patients reviewed at our insti-
tution, six patients (21%) who received combi-
nation therapy experienced improvement in
mood, with no or minimal tolerable adverse
effects. Only one of these patients was receiving
transdermal selegiline (Table 3, case 4), whereas
four were treated with tranylcypromine
(Table 4, cases 5, 8, 11, and 13) and one with
phenelzine (Table 4, case 12). Similarly, seven
patients (24%) demonstrated no or minimal
improvements in mood. Documented adverse
effects requiring discontinuation of one or more
of the medications occurred in 13 patients
(45%), including three suspected cases of seroto-
nin syndrome, which were neither confirmed
nor required acute intervention. Two patients
using the selegiline patch discontinued treatment
due to rash and other reasons. There were no
reports of major serious consequences due to
combination therapy with MAOIs. The most
common adverse effects included hypotension,
constipation, fatigue, dry mouth, and dizziness.
The most frequent combinations included either
trazodone or a TCA combined with an MAOI,
sometimes with an additional psychotropic
agent. The average duration of therapy for com-
bination MAOI with trazodone was 21 months.
At the time of this writing, the majority of
patients receiving combination treatment with
an MAOI, a TCA, and possibly another antide-
pressant were still taking the combination, with
the exception of two cases.
Discussion
The following highlights the findings from
both the literature review and our case series.
There were six combinations encountered, con-
sisting of MAOIs in combination with other an-
tidepressants and/or stimulants.
MAOI plus SSRI/SNRI
There is a paucity of controlled, prospective
data on combination therapy with an MAOI and
a selective serotonin reuptake inhibitor (SSRI)
or serotonin and norepinephrine reuptake inhib-
itor (SNRI) due to the general recommendations
to avoid combination use. Combination therapy
of MAOIs and SSRIs or SNRIs is dangerous due
to the increased risk for serotonin syn-
drome.6, 33, 34 Further, deaths associated with
combination use involving SSRIs have been
reported in patients receiving therapeutic and
overdose amounts.35, 36 To avoid this, it is rec-
ommended that SSRIs or SNRIs be discontinued
for at least 2 weeks before beginning MAOI
therapy, with the exception of fluoxetine, which
requires a 5-week washout period.37 Our single
case of fluoxetine combined with an MAOI was
uninformative (see details in Table 3, case 1), as
the MAOI was discontinued at an outside hospi-
tal for unknown reasons. Further, in case 1 in
Table 4 and case 2 in Table 3, when the SNRIs
venlafaxine and duloxetine were used in combi-
nation with an MAOI and trazodone, no positive
outcomes were noted. Data support avoiding
combinations of SSRIs or SNRIs with MAOIs
(regardless of MAO selectivity), as the risk most
often exceeds any potential benefit, particularly
with concomitant use of trazodone.6, 15, 16, 33
MAOI plus Trazodone
Trazodone is effective for sleep, and an open-
label study and case series have shown that
low-dose trazodone may be a safe and effective
treatment option for insomnia associated with
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MAOI use.17–19 There are limited data on the
use of higher doses of trazodone in combination
with MAOIs for TRD.18, 19 Overall, our cases
also support safe and effective use of low-dose
trazodone and MAOIs. It should be noted that
the trazodone doses used are largely targeting
insomnia and are not effective antidepressant
doses. The addition of low-dose trazodone to
MAOI therapy appeared to improve tolerability
of the MAOI and overall clinical improvement of
patients. Reasons for discontinuation of trazo-
done and MAOI combination therapy in our
review included ineffectiveness, feeling overly
tired, experiencing more sleep disturbance, or
cognitive clouding. One patient we described in
our case series stopped trazodone and MAOI
combination treatment due to symptoms consis-
tent with serotonin syndrome, although this was
not definitively diagnosed (Table 4, case 2).
Overall, however, patients receiving this combi-
nation averaged approximately 21 months of uti-
lization. Further studies are needed, and the
risks of combination treatment should remain a
concern, including the risk of orthostatic hypo-
tension, which should be monitored closely. It
should be noted that higher doses of trazodone
are likely associated with greater risk of seroto-
nin syndrome, and the risk would likely out-
weigh potential benefit in most cases.
MAOI plus TCA
The literature on TCA-and-MAOI combination
therapy is mixed. Small studies and case reports
have demonstrated its safety, but the combina-
tion has generally been found to be less well tol-
erated than either agent alone.20–22 In addition,
there are studies that suggest that the combina-
tion is no more efficacious than either agent
alone and should be reserved for individuals
with high depression scores, TRD, or atypical
depression.20–22 Our patients who received TCA
and MAOI combination therapy show sustained
tolerability and efficacy (Table 3, cases 13–15;
Table 4, cases 10–13). Three of the seven
patients remained on this regimen for at least
2 years, two of whom also received trazodone in
combination with the TCA and MAOI. The com-
bination was discontinued in four patients due
to one case of hypotension (patient was also
receiving trazodone), one case with suspicion of
serotonin syndrome, one patient who experi-
enced fatigue with the combination, and one
patient who could not tolerate pruritis associated
with the selegiline patch. These results support
existing data that this combination is relatively
safe, with variable efficacies. If this combination
is used, the TCA should be initiated first or at
the same time as the MAOI.9 It should be noted
here that clomipramine, a TCA, exhibits potent
inhibition of serotonin should not be used in
combination with an MAOI.38
MAOI plus Bupropion
There are three existing cases published
reporting on the use of bupropion and tranylcy-
promine in combination.26, 27 Each of these
cases resulted in improvement in depressive
symptoms without reports of hypertension or
other problematic adverse effects. Among the
cases in our study, one patient continued combi-
nation treatment with bupropion and selegiline
beyond 1 month, but efficacy was not well docu-
mented (Table 3, case 10). Of note, this patient
was receiving transdermal selegiline, which
poses a lower risk for hypertensive crisis due to
its increased selectivity for MAO-B at this low
dose, as previously highlighted. As such, it is
not as sensitive to dietary tyramine intake as
higher doses of transdermal or oral selegiline or
other nonselective MAOIs. Two additional
patients receiving bupropion in our case series
did not demonstrate benefit with combination
treatment (Table 3, cases 11–12). Given the lim-
ited published evidence, bupropion in combina-
tion with an MAOI may be considered; however,
the risk for hypertension or other adverse effects
should be monitored closely, and additional
studies of this combination are needed.
MAOI plus Stimulants
Stimulants have been used safely in combi-
nation with MAOIs. Although stimulants are
not indicated for the treatment of depression,
these agents are used in clinical practice as an
augmentation strategy for TRD.39 The litera-
ture, of which the majority consists of case
reports and case series, supports the use of
stimulants in combination with an MAOI.28–30
Stimulants may help to normalize blood pres-
sure in those experiencing hypotension as a
result of MAOI therapy. It should be noted
that our case series did not highlight this
combination. As with the other MAOI combi-
nations, this should be reserved for treatment-
resistant patients under the supervision of a
qualified and experienced clinician, carefully
assessing risk versus benefit.
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MAOI plus Antidepressants plus Stimulants
The use of direct stimulants in combination
with an MAOI plus another antidepressant has
demonstrated safety and efficacy in case
reports.31, 32 Our patients showed mixed results.
One patient taking amphetamine in addition to
an MAOI and another antidepressant remained
stable on this combination for longer than
10 months (Table 3, case 4). Another patient
taking methylphenidate in addition to an MAOI
and two antidepressants discontinued one of the
antidepressants due to symptomatic hypotension
and tachycardia, but the rest of her regimen
remained the same (Table 4, case 10). The addi-
tion of stimulants to MAOI therapy has generally
been avoided by physicians given the risk of
hypertensive and hyperthermic crises. Blood
pressure should be monitored closely as well as
signs of other adverse effects. Similar to other
combinations, this approach should be used
with caution and under the supervision of a
qualified and experienced clinician, particularly
as a last resort option, including failure of elec-
troconvulsive therapy.
Limitations
The limitations of a retrospective case series
highlight recall bias and the nature of recorded
clinical information. In the information we
reviewed, patients may not have recollected their
full diet or use of over-the-counter medications
that may have contributed to adverse events. This
potentially results in inaccurate records and thus
adverse effects associated with diet, and medica-
tions prescribed by providers outside of our sys-
tem may have been missed. As a retrospective
case series, our data are strictly limited to medi-
cal records. Loss of patient follow-up could be
mistaken as discontinuation of therapy, and the
retrospective nature also relies on clear documen-
tation in the medical record. Other limitations
include variability among patients. Each patient
presented with various depression severities,
medications, formulations (patch vs oral, and
selective vs nonselective MAO inhibition), and
dosing regimens. These variances prevent the
ability to make strong general conclusions on
specific combination treatments.
Conclusion
Our case series and review of the literature
suggest that when used under close supervision
and under the care of an experienced clinician
in psychiatry, combination therapy with MAOIs
and other antidepressants (with the exception of
SSRIs, SNRIs, or clomipramine) or stimulants
may be a consideration for the challenging man-
agement of TRD in patients not responding to
monotherapy or other combinations of antide-
pressants or augmentation strategies.
Two recent studies evaluated the use of the
MAO type B inhibitor rasagiline in patients with
Parkinson’s disease in combination with various
antidepressants and found no reports of serotonin
toxicity.40, 41 Coverage of this topic is important;
however, recent literature to provide guidance on
how to safely ude MAOIs for TRD in combination
with other antidepressants or stimulant medica-
tions is sparse. The emerging use of electronic
patient records offers the opportunity to gather
therapeutic and outcomes data on larger numbers
of patients. It is unlikely that clinical trials with a
translational focus will be sponsored to study
MAOIs and other currently used antidepressants
in TRD. This is unfortunate, as longitudinal stud-
ies of individuals with TRD are needed and ide-
ally will include embedded randomized
controlled trials with combination treatment that
includes MAOIs and other pharmacologic strate-
gies. Focused environmental and pharmacologic
inquiry aimed at determining why treatment
resistance occurs and is sustained is needed. Our
study with one health system shows that the data
are accessible and that with existing data mining
methods, we were able to show that one in five
patients with TRD responded to a combination of
an MAOI and other antidepressant. This is of
major importance given that depression is so
common and the finding that depression is the
largest cause of disability and disability-adjusted
life-years worldwide;42, 43 disability due to
depression is most likely TRD.
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